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Abstract
Background: The purpose of this study will be to improve diabetes prevention, access to care and advocacy
through a novel cost-effective nurse-led continuum of care approach that incorporates diabetes prevention,
awareness, screening and management for low-income settings, and furthermore utilizes the endeavor to advocate
for establishing a standard diabetes program in Nepal.
Methods: We will conduct a two-arm, parallel group, stratified cluster randomized controlled trial of the NUrse-led
COntinuum of care for people with Diabetes (N1 = 200) and prediabetes (N2 = 1036) (NUCOD) program, with
primary care centers (9 outreach centers and 17 government health posts) as a unit of randomization. The NUCOD
program will be delivered through the trained diabetes nurses in the community to the intervention group and the
outcomes will be compared with the usual treatment group at 6 and 12 months of the intervention. The primary
outcome will be the change in glycated hemoglobin (HbA1c) level among diabetes individuals and progression to
type 2 diabetes among prediabetes individuals, and implementation outcomes measured using the RE-AIM (reach,
effectiveness, adoption, implementation and maintenance) framework. Outcomes will be analyzed on an intention-
to-treat basis.
Discussion: The results of this trial will provide information about the effectiveness of the NUCOD program in
improving clinical outcomes for diabetes and prediabetes individuals, and implementation outcomes for the
organization. The continuum of care model can be used for the prevention and management of diabetes and
other noncommunicable diseases within and beyond Nepal with similar context.
Trial registration: ClinicalTrials.gov, NCT04131257. Registered on 18 October 2019.
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Background
Prevalence of type 2 diabetes (hereafter, diabetes) has
been rising like a silent epidemic in Nepal, similar to
other developing countries. A systematic review and
meta-analysis reported a pooled prevalence of type 2 dia-
betes of 8.4% (95% CI: 6.2–10.5%) [1]. It is estimated
that between 1990 and 2010 the burden of diabetes in-
creased by about 89% in Nepal [2].
The most recently published Disease Control Priority-3
(DCP-3) systematically reviewed available interventions
for diabetes in resource-limited settings, and strongly rec-
ommended the following interventions based on their
cost-effectiveness and feasibility: targeted (two-step)
screening for both prediabetes and diabetes; blood pres-
sure control among people with diabetes; lifestyle inter-
ventions to prevent diabetes among high-risk individuals;
and good glycemic control along with smoking cessation
and foot care. Those interventions, ranging from case de-
tection to prevention of diabetes among those at high risk,
to diabetes management and to screening for preventing
diabetes complications, have been extensively tested for
efficacy and cost-effectiveness. However, the DCP-3
pointed out two knowledge gaps: little evidence for the
testing of the effectiveness of those interventions in low-
income settings; and a lack of implementation-oriented
research for adopting and scaling up those interventions.
This is compounded by the fact that a chronic disease like
diabetes needs a structured, well-concerted comprehen-
sive approach comprising continuum of care prevention
activities, timely screening, standard clinical management
and self-management skills for lifestyle modification ra-
ther than segregated interventions. Nurse care coordina-
tors have been found to improve patient and health
service outcomes, particularly when they frequently inter-
acted with the patients, conducted follow-up with moni-
toring and education of the disease and behavioral
changes, and were involved in transition care [3–7]. How-
ever, they often focused on specific components rather
than the full spectrum of the continuum of care for the
patient. Also, studies are rarely conducted in low-income
countries.
The Dhulikhel Hospital (DH) system is a community-
oriented, nongovernmental health system with an exten-
sive network of 21 rural community-based outreach cen-
ters. The DH system provides a well-suited setting for
innovating a continuum of care for people with diabetes.
In this trial, we aim to develop and implement a “con-
tinuum of care” program with trained nurses as the nu-
cleus. The nurses, along with the community health
worker, will coordinate and implement a composite of
the DCP-3-recommended individual intervention com-
ponents for the low-income setting: leading community
awareness campaigns; organizing diabetes screening
events; linking diabetic patients to comprehensive
clinical care (which will have been structured based on
standard guidelines); and ensuring treatment adherence
and self-management through regular community-based
group counseling programs. The primary objective of
this study is to examine the effectiveness of this compre-
hensive intervention in promoting the health of the
people with diabetes and prediabetes, and the secondary
objective is to examine whether the nurse coordination
will promote the implementation of the evidence-based,
DCP-3-recommended interventions. We hypothesize
that the NUrse-led COntinuum of care for people with
Diabetes and prediabetes (NUCOD) program will im-
prove both clinical outcomes as well as implementation




This study will be a two-armed, parallel group, stratified
cluster randomized controlled trial (RCT) of the
NUCOD program (Fig. 1), with the health center as a
unit of randomization. We will use a computer-
generated list of random numbers to randomize health
centers stratified by Kathmandu University (KU) out-
reach centers and government health posts, whereby all
patients from the same health center will be allocated to
the same group. The study will be planned and imple-
mented in concordance with the Consolidated Standards
of Reporting Trials (CONSORT) cluster trial extension
statement [8] and the Standards for Reporting Imple-
mentation Studies (StaRI) statement [9]. We plan to use
the cluster design to reduce between-group contamin-
ation and spillover effects of the intervention as well as
to align the design with the natural project implementa-
tion unit based on the cluster.
Setting
The study will be conducted in 26 clusters: 9 outreach
centers (Bahunepati, Manekharka, Hindi Health, Baluwa,
Bolde Phediche, Dapcha, Kartike Deurali, Salambu and
Dhunkharka Health Centers) of Dhulikhel Hospital,
Kathmandu University Hospital and 17 government
health posts located in the adjoining catchment areas pur-
posively selected from the Kavrepalanchowk and Sindhu-
palchowk districts. The primary stratification variable, as
well as the unit (cluster) of randomization and implemen-
tation, will be health clinics (outreach centers and health
posts (HPs)). There will be 13 clusters per treatment arm
(1:1 allocation ratio). Outreach centers are the small med-
ical health facilities that offer basic and emergency care
services in remote areas of Nepal. These centers are run
by Kathmandu University Hospital. Similarly, health posts
are government-run facilities that provide basic health
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Fig. 1 Summary of the trial design for the NUCOD program. BMI body mass index, HbA1c hemoglobin A1c (aka glycated hemoglobin), NUCOD
NUrse-led COntinuum of care for people with Diabetes and prediabetes
Fig. 2 Map of Kavre District with outreach centers of Dhulikhel Hospital and government facilities. ORC outreach center
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care and preventive medication in remote rural areas of
Nepal.
Kavrepalanchowk district located in Province 3 of
Nepal consists of 13 municipalities: 6 urban and 7 rural
municipalities with a total of 137 wards. The headquar-
ter of this district is Dhulikhel municipality. A total
population of 381,937 resides in this district; 62.51% live
in the urban municipalities and 37.49% live in the rural
municipalities. There is one 15-bed district hospital, 4
primary health care (PHC) centers and 86 HPs in the
district [10]. Sindhupalchowk district, also located in
Province 3 of Nepal, consists of 12 municipalities: 3
urban and 9 rural municipalities with a total of 103
wards. The headquarter of Sindhupalchowk district is
Chautara. A total population of 287,798 resides in this
district; 41.42% live in the urban municipalities and
58.58% live in the rural municipalities. There is one 15-
bed district hospital, 3 PHC centers and 75 HPs in the
district [10]. The maps of Kavrepalanchowk and Sindhu-
palchowk districts with the distribution of outreach cen-
ters and health posts are shown in Figs. 2 and 3.
Participants
Eligibility criteria for health centers/health posts
 Outreach centers/health posts located in the
Kavrepalanchowk and Sindhupalchowk districts
 Have a nurse (staff nurse or auxiliary nurse midwife
(ANM))
Eligibility criteria for participants
To resemble the real-world settings as much as possible,
we will apply the minimum inclusion and exclusion cri-
teria for the participants. Individual with confirmed pre-
existing type II diabetes and prediabetes at the time of
our screening (i.e., pre-existing diabetes or prediabetes)
or with a confirmed diagnosis of type II diabetes or pre-
diabetes after our community screening process (i.e.,
newly diagnosed diabetes and prediabetes), who is not
planning to relocate outside the current place of living
in next 2 years and is older than 18 years of age, will be
eligible for project recruitment. People will be excluded
if they: are not psychologically capable of communica-
tion; and are diagnosed with type 1 diabetes. Participants
will be assessed for the risk of diabetes using the Indian
Diabetes Risk Score (IDRS) [11]. Anyone identified as at
risk will undergo a random finger-prick glucose test
followed by the hemoglobin A1c (HbA1c) test. The diag-
nosis will be confirmed by an HbA1c level ≥ 6.5% for
diabetes or between 5.7 and 6.4% for prediabetes [12].
Screening and recruitment
The program will be rolled out with each outreach cen-
ter/health post serving as the implementation unit. The
program participants will be recruited through a
community-based screening effort. Information regard-
ing the screening event will be disseminated at the time
of the awareness campaign. Trained diabetes nurses will
screen the general population at the outreach center/
health post, and those who screen positive will be
Fig. 3 Map of Sindhupalchowk District with outreach centers of Dhulikhel Hospital and government facilities. ORC outreach center
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referred to the DH diabetes clinic for further tests and
for program recruitment if eligible for the study. All of
the screening procedures including laboratory investiga-
tions and anthropometric measurements will be carried
out at the respective centers, and all of the longitudinal
data of patients will be entered into an electronic health
record (EHR) system for data storage and management.
Each participant will be assigned a unique identification
number at the time of enrollment. All data collected as
part of this study will be identified with this number. Re-
search assistants (RAs) will be responsible for obtaining
the signed informed consent form from the participants.
On the consent form, participants will be asked whether
they agree to use of their data should they choose to
withdraw from the trial. Participants will also be asked
for permission for the research team to share relevant
data with people from the universities taking part in the
research or from regulatory authorities, where relevant.
This trial involves collecting biological specimens for
storage.
Recruitment will be primarily through conducting dia-
betes awareness mass campaigns in the targeted sites of
the two districts to achieve adequate participant enroll-
ment. We intend to reach 50,000 people (approximately
2000 people at each of the 9 outreach centers and 17
health posts). Interested candidates will contact the
study nurses, who will provide them with basic informa-
tion about participation, including information on the
screening process, time commitment and expectations
associated with participation. Assuming 25% of those
who are made aware of diabetes will participate in the
screening (see later for the details of screening methods),
we target screening 12,500 participants. The two-step
screening approach will be used for the study after asses-
sing the risk of diabetes among the individuals using the
IDRS assessment tool. In the first step, anyone under
risk will undergo a random finger-prick blood glucose
test using Beurer glucometers [13]. A random blood
sugar level of 200 mg/dl or higher will be considered
positive for diabetes and a sugar level of 140–199mg/dl
will be considered positive for prediabetes [12]. In the
second step, participants screened positive for a random
blood glucose level will undergo a glycosylated
hemoglobin (HbA1c) test. An HbA1c level between 5.7
and 6.4% will be considered positive for prediabetes and
an HbA1c level of 6.5% or above will be considered
positive for diabetes [12]. Participants with HbA1c
level ≥ 5.7% will be invited to participate in the study.
Based on the earlier quoted prevalences of 8.4% (95%
CI: 6.2–10.5%) for diabetes [1] and 13% (95% CI:
11.8–14.5%) for prediabetes [14], we expect to identify
1050 (12,500 × 0.084) individuals with diabetes and
1625 (12,500 × 0.13) individuals with prediabetes for
this study.
Randomization
The 26 health clinics will be randomized 1:1 into the
continuum of care group (intervention) and the usual
care group (control), stratified by outreach center and
health post. The usual care group includes those who
continue managing their diabetes under the direction of
their primary care providers, which is the most com-
monly used method for diabetes management in Nepal.
The selection of the usual care group as a comparator is
thus justified. A statistician otherwise not involved in
the project will perform this group assignment at the
cluster level with simple random selection with the R
statistical program. Randomization will be done before
participant recruitment. Outcome assessors will be
blinded to the group assignment, but the nurses and pa-
tient participants will be aware of their group assign-
ment. If blinding to the outcome assessor is accidentally
broken, they will follow a standard protocol for reassess-
ment of the patients at another time. Any violations of
the study protocol will be recorded and reported to the
Ethics Committee.
Baseline assessment
At baseline, trained RAs will interview the participants
using a standardized electronic questionnaire on Comm-
Care, a mobile platform designed for data collection
[15]. RAs will receive 2 weeks of training in data collec-
tion and ethical issues. The questionnaire will assess so-
cioeconomic characteristics including age, sex, ethnicity,
religion, marital status, annual income, education level
and family history, and lifestyle factors including smok-
ing, alcohol intake and physical activity. We will use the
Global Physical Activity Questionnaire [16] to calculate
the metabolic equivalent of task (MET) minutes per
week. A weekly MET equivalent of 600 would represent
30 min of brisk walking five times per week or 15min of
running five times per week. We will use PrimeScreen
questionnaire [17], a short diet assessment tool to assess
the diet quality of the study participants. Body weight
will be measured with minimum clothing and without
shoes using an Omron Model HBF-400 scale and re-
corded to the nearest 0.1 pounds. The weighing scale
will be calibrated to zero every day. Participants’ heights
will be measured, without shoes, while the participants
stand against a wall. Height will be measured using a
tape measure and recorded to the nearest 0.1 cm.
Blood samples will be collected for HbA1c, low-
density lipoprotein (LDL), high-density lipoprotein
(HDL), triglycerides and total cholesterol at each re-
spective health center where all the laboratory proce-
dures will be carried out. Blood samples will be collected
using evacuated blood collection tubes. Participants will
be asked to fast overnight (8–14 h).
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Intervention: NUCOD program components
The intervention will be delivered by specially trained
nurses from Dhulikhel Hospital (DH). The interven-
tion has been developed based on our extensive lit-
erature review and the recommendations from the
Disease Control Priorities-3 (DCP-3) as well as an
analysis of local contexts in consultation with various
stakeholders. The intervention will include the follow-
ing components, logically sequenced as a continuum
of care approach. Figure 4 presents the major pro-
gram components. The nurses will act as the leader
and coordinator for the implementation of all the
program components:
▪ Training of nurses: by drawing from standard training
manuals published by the International Diabetes
Federation and American Diabetes Association, the
project management team will first develop a protocol
and content for the training of nurses for this program.
This training protocol will be tailored to the context of
Nepal and will include case studies and examples
relevant to Nepal. The training will focus on clinical as
well as case management skills. We will train 26 nurses
(one for each site) into diabetes nurses using this
training protocol.
▪ Community awareness campaigns: the nurses will lead
the organization of a mass campaign on diabetes in
coordination with local newspapers, radio stations,
youth groups, municipality offices, district health offices
and other health facilities. The campaigns will, in
particular, include a simple diabetes risk factor
assessment tool to be adapted from the Type 2
Diabetes Risk Test (DRT) of the American Diabetes
Association [18]. The campaign will encourage people
with high risk to attend the screening program.
▪ Screening programs: the nurses will organize screening
programs for both diabetes and prediabetes for the
community members on specific dates and sites, which
will be communicated beforehand to the people in the
locality. The screening will be done in coordination
with the clinical biochemistry department of DH.
▪ Linkage to clinical care: people who screened positive
for diabetes and prediabetes (pre-existing as well as
new) will be linked to the DH clinic by nurses, where
they will be recruited into the program and will receive
their group assignment. People assigned to the control
group will follow the usual procedure, while those
assigned to the intervention group will attend a 1-h
nurse-led counseling session on diabetic care. The pa-
tients will be responsible for their medical costs
Fig. 4 Intervention components of the NUCOD program. DH Dhulikhel Hospital, NUCOD NUrse-led COntinuum of care for people with Diabetes
and prediabetes
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(laboratory investigations and medicine), while people
experiencing financial hardship can apply for charity
care (free or at a reduced price) with guidance from the
nurse. The assigned nurse will be responsible for deter-
mining their financial profile by reviewing the annual
household income, applicable assets, available insurance
coverage and confirmation of other sources of
payment.
▪ Community follow-up counseling and support for the
diabetic patients: the nurse will organize diabetic
patients into groups of 10 and arrange bimonthly
meetings (each 2 h in length) in which the patients will
be facilitated using the 5A framework (Assess, Advise,
Agree, Assist and Arrange follow-up) to adopt a healthy
lifestyle (dietary changes, physical activity, cessation of
smoking, etc.) [19]. In addition to the lifestyle changes,
the participants will also be facilitated to adhere to
medical advice (timely follow-up, adherence to medica-
tions, etc.). The nurses will also coordinate with the
diabetes clinic at the hospital to ensure that the clinical
care and the community-level interventions comple-
ment each other. They will also have an electronic tab-
let that has all the details (laboratory results, behavioral
parameters, anthropometric measures, etc.) of the par-
ticipants so that the progress of the participants in
these parameters can be recorded and assessed.
▪ Prevention programs for prediabetic participants: in
addition to the people with diabetes, the nurses will
also form groups of prediabetes participants and will
arrange monthly meetings to help facilitate the
adoption of a healthy lifestyle using the Diabetes
Prevention Program (DPP) curriculum. The DPP
lifestyle intervention has been associated with
significantly reducing the development of diabetes
through its structured behavior-changing approaches
[20]. A multidisciplinary team of dieticians and physical
therapists will assist with the other components of the
DPP program that are related to nutrition and physical
activity.
The control group will receive the usual diabetic care,
which includes the same hospital quality improvement
for diabetic care as already mentioned, the follow-up ser-
vices from the female community health volunteers
(FCHVs) (but without the nurse coordination and super-
vision as in the intervention group) in addition to the
usual care. FCHVs are the grass-roots level of commu-
nity health workers in Nepal who play important roles in
the implementation of community-based programs, in-
cluding screening for high-risk cases, referring people to
local health facilities and maintaining a record of health
activities [21]. The program comparison of the interven-
tion group versus the control group is summarized in
Table 1.
Outcome measures
We will examine both clinical outcomes and implemen-
tation outcomes as we hypothesize that the nurse-led
continuum of care program will improve both health
and the implementation of priority interventions in dia-
betes. The outcome measure will pertain to the individ-
ual participant level. The primary outcome for the
diabetes group is the HbA1c level at 12 months from
the intervention. The HbA1c level is indicative of the
average level of blood glucose over the past 2–3
months [22]. The primary outcome for the prediabe-
tes group is the incidence of diabetes at 12 months
from the intervention.
The secondary outcomes are blood pressure, body
mass index (BMI) and lipid levels. Also, the secondary
outcomes include a series of implementation outcomes
in the RE-AIM (reach, effectiveness, adoption, imple-
mentation, and maintenance) implementation frame-
work [23–25]. We provide details on those measures in
the following (see Table 2 for a summary).
Clinical outcomes
The clinicians from Dhulikhel Hospital outreach centers
not otherwise associated with the project will measure
HbA1c, lipid profiles, BMI and blood pressure when the
participants visit the diabetic clinic at baseline, 6 months
and 12months.
HbA1c will be measured using Boronate affinity chro-
matography (Axis-Shield; Norway) [26], LDL and HDL
using the elimination method (Dialab; Austria) [27], tri-
glyceride using GPO-PAP (Dialab; Austria) [28] and
total cholesterol using CHOD-PAP (Dialab; Austria)
[29]. For each type of assay, the laboratory has quality
control (QC) materials (using commercially available
assayed and unassayed control material) from Bio-Rad










Linkage to clinical care x
• Coordinated through the nurses x
• provided by FCHVs without involvement of
the nurse
x
Improved quality of care at the hospital x x
Nurse-led counseling x
Community follow-up coordinated through the
nurses
x
Prevention program to prediabetics through the
nurses
x
FCHV female community health volunteer
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Laboratories, USA. Each QC is run at least in dupli-
cate. External QC is arranged by internationally rec-
ognized reference laboratories that distribute batches
of samples of various concentrations for each assay.
The laboratory performs the External Quality Assur-
ance Scheme from an unknown assayed sample from
the Department of Clinical Biochemistry CMC, Vel-
lore, India for 23 routine parameters, 5 immuno-
logical parameters and HbA1c. Additionally, 5% of
the blood samples will be obtained in duplicate and
sent for testing of all parameters, blinded to the la-
boratory personnel.
The mean of three measurements of systolic and
diastolic blood pressure, using a Microlife automatic
blood pressure measuring device, will be adopted for
analysis. Hypertension is defined as systolic blood
pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90
mmHg or taking antihypertensive medication [30].
Weight will be measured and recorded to the nearest
0.1 kg, without shoes and with minimum clothing,
using an Omron Model HBF-400 scale. Height will be
measured without shoes using a standard tape meas-
ure with participants standing against a wall for
measurement, and recorded to the nearest 0.1 cm.
The BMI will be calculated as weight in kilograms di-
vided by height in meters squared. Overweight is de-
fined as a BMI of 25 kg/m2 or higher and obesity is
defined as BMI of 30 kg/m2 or higher based on inter-
national cutoff points [31].
Implementation outcomes
The RE-AIM (Reach, Effectiveness, Adoption, Imple-
mentation, and Maintenance) framework will be imple-
mented as follows:
 Reach will be measured by the number of people
participating in the program divided by the number
of people eligible to be recruited into the program.
 Effectiveness will be represented by the clinical
outcomes.
 Adoption at the patient level will be measured by the
proportion of people adherent to the clinical advice
in lifestyle and self-care—this will be measured by
the self-reported Summary of Diabetes Self-Care Ac-
tivities (SDSCA) scale [32] at baseline, 6 months and
12 months (the SDSCA measure is a brief self-report
questionnaire that includes items assessing general
diet, specific diet, exercise, blood-glucose testing,
foot care and smoking) and, in addition, the Dia-
betes Treatment Satisfaction Questionnaire
(DTSQ) [33] will be administered at baseline, 6
months and 12 months (the DTSQ is the most
commonly used patient-reported outcome in dia-
betes trials, which reflects the patient’s perception
of the treatment)—and at the clinic level will be
measured by the proportion of health clinics suc-
cessfully recruited into the program over the
clinics eligible and approached to participate in
the program.
Table 2 Measures of outcome variables







Glycemic control (HbA1c)a for diabetes Blood sample Biochemist x x x Continuous
Incidence of diabetes among prediabetes EHR RA/nurse x x Binary
Secondary outcomes
Blood pressure Electronic monitor RA/nurse x X x Continuous
Lipid profile Blood sample Biochemist x X x Continuous
Body mass index EHRb RA/nurse x x x Continuous
Implementation outcomes
Reach Log recordc RA/nurse x x Continuous
Adoption SDSCA/DTSQ RA/nurse x x x Binary
Implementation (fidelity) Checklist SP x x Continuous
Self-monitoring of glucose Self-reported RA/nurse x x Binary
Medication adherence Self-reported RA/nurse x x Binary
DTSQ Diabetes Treatment Satisfaction Questionnaire, EHR electronic health record, HbA1c hemoglobin A1c (aka glycated hemoglobin), RA research assistant,
SDSCA Summary of Diabetes Self-Care Activities Assessment, SP standardized patient
aThe average level of blood sugar over the past 2–3 months
bCalculated as weight in kilograms divided by height in meters squared
cNumber of people participating in the program divided by the number of people eligible to be recruited into the program
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 Implementation will examine the fidelity and quality
of the program execution per protocol. To check
program fidelity, we will select and train
standardized patients (SPs) from the program
participants with stable conditions—these SPs will
serve as the “secret agents” and the sentry to assess
program fidelity with a quality checklist through
their routine encounters with the clinicians at the
DH diabetes clinic and the nurses; the clinicians will
be blinded to the status of the SPs; and the
development of SPs and the checklist will follow the
protocol we have developed in a separate study [34].
 Maintenance will not be assessed for the purpose of
this study.
The hospital and program administrative system will
collect a range of other information including detailed
program costs, health service utilization and incidence of
complications and comorbidities. All data will be entered
and securely stored in the EHR, a secured online data
capturing and management system developed for the
study at the DH.
Sample size
In this proposed community-based intervention, changes
in the HbA1c levels (continuous outcome) were consid-
ered for calculating the sample size for the individuals
with diabetes and the incidence of diabetes (binary out-
come) was considered for calculating the sample size for
the individuals with prediabetes, respectively. For the in-
dividuals with diabetes, we aim to detect a clinically sig-
nificant reduction in HbA1c levels from 7.6% to 6.5%
(SD = 1.5%) (based on our assumption, the recom-
mended effective diabetic management level and results
of previous studies) among the individuals with diabetes
during the 12-month period [35, 36] with medium effect
size [37]. We expect a reduction of HbA1c to 7.0% in
the control group, an optimal target level defined by the
American Diabetes Association (ADA) [38]. Setting the
statistical significance at the 0.05 level, seeking 90%
power, with an intraclass correlation coefficient (ICC) of
0.01 based on a previous study conducted in Nepal [39],
an average cluster size of 50 (individuals with diabetes)
based on preliminary data from the awareness and
screening campaign, a design effect for clustering of 1.49
and a design effect for unequal cluster size of 1.52 (coef-
ficient of variation of cluster size 0.25), 91 people with
diabetes per arm (182 total) will be required for the
study. For the incidence of diabetes among people with
prediabetes (dichotomous outcome), we considered the
incidence of 10% and 2%, respectively, for the two
groups; stated as a range in an earlier study [40]. Based
on these considerations, 471 people with prediabetes per
arm (942 total) will be required. We expect a dropout
rate of 10% from baseline to 12-month follow-up; hence,
we will need to recruit a total of 200 diabetes and 1036
prediabetes participants (total sample size = 1236 partici-
pants). The sample size for our cluster RCT was calcu-
lated using the following equation. Details of the sample
size estimation is available in another study conducted
by Ribeiro et al. [41]:
SScluster RCT ¼ SSstandard RCT  DEcluster  DEunequal
where SScluster RCT = total sample size for a cluster RCT;
SSstandard RCT = total sample size for a standard RCT
(equal to (Z1 – α / 2 + Z1 − β)
2 2σ2 / Δ2, where Zx is the
xth percentage point of the standard normal distribu-
tion, Δ is the clinically important difference in treatment
means and σ2 is the variance in the outcome); DEcluster =
design effect for clustering (equal to 1 + ICC × (m – 1),
where m is the number per site); and DEunequal = design
effect for unequal cluster size (equal to 1 + [(1 + cv2) ×
m − 1] × ICC, where cv is the coefficient of variation of
cluster size and m is the mean cluster size).
Statistical analysis
Data will be analyzed at the individual (patient) level.
Statistical analyses will be performed using the
intention-to-treat (ITT) approach in the originally
assigned groups. Demographic and baseline characteris-
tics for the intervention and control groups will be pre-
sented in the form of mean (standard deviation (SD)) or
95% confidence intervals (CIs) for continuous variables
and counts (percentages) for categorical variables. ITT
analysis will be performed on the final data collected at
12 months.
Generalized estimating equations (GEEs) with cluster-
ing by site, an exchangeable correlation matrix and ro-
bust variances will be used to assess the program effect
adjusting for potential baseline covariates. The model
will take account of clustering and will be used to look
at the difference between groups for the HbA1c level at
6 and 12 months, respectively. Multiple imputation will
be used to account for the missing values assuming they
are missing at random. To test for the secondary sensi-
tivity analysis, data will be analyzed without multiple im-
putation and without baseline covariate adjustment. The
difference in the incidence of diabetes between the
groups among the individuals with prediabetes will be
tested using a GEE. Statistical significance will be
assessed at the 5% level and all analyses will be two-
sided. All data analyses will be performed using the Stata
15 (StataCorp, TX, USA) statistical software program.
As we expect that the program effect may differ be-
tween several subgroups of the program participants, we
plan to do secondary analyses of the following three sub-
groups for the primary (HbA1C) and secondary
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(incidence of diabetes) outcomes: the subgroups with
poor initial glycemic level (HbA1c ≥ 5.7%) (people with
poorer glycemic level at baseline may have a stronger
desire to change their behavior); the subgroups divided
by gender (in Nepal, women tend to be more adherent
to clinician guidance); the subgroups of different social
economic classes (people in higher socioeconomic class
may be more likely to adhere to lifestyle changes); and
government versus nongovernment health centers. The
secondary analyses will compare the HbA1c level and in-
cidence of diabetes among people with prediabetes
among these subgroups at the end of the 12-month
intervention using the generalized linear mixed models
with a random cluster effect and adjusting for potential
confounders.
Descriptive statistics (i.e., counts, means and propor-
tions) will be calculated to evaluate the reach, effective-
ness, adoption and implementation of the program.
Economic analysis
Cost-effectiveness analysis will also be conducted with a
Markov simulation model to be developed. The Markov
model has been widely used to describe the development
of the chronic noncommunicable diseases [42]. All direct
costs (e.g., screening cost, cost of training of nurses and
cost of EHR system development) and indirect costs will
be collected. All costs will be reported in 2020 US dol-
lars using the exchange rate of 1 USD = 111.7 NPR. We
will solve the model numerically over a short and long
timeframe (i.e., 10 years and 20 years), and calculate the
incidence of diabetes, costs and quality-adjusted-life-
years (QALYs) under the control case or the NUCOD
program. Incremental QALY and costs of the NUCOD
program relative to the control case will be calculated
with an annual discount rate of 3%. We will use WHO-
CHOICE (Choosing Interventions that are Cost-
Effective) thresholds for cost-effectiveness: an interven-
tion is defined as “cost-effective” if it produces a healthy
life year for less than three times the gross domestic
product (GDP) per capita, and as “very cost-effective” if
it produces a healthy life year for less than the GDP per
capita [43, 44].
Data monitoring and quality assurance
The trial will receive overall supervision from a Trial
Steering Committee (TSC) who will conduct quarterly
on-site monitoring of health clinics (with repeat visits to
sites where performance is a concern), monitor trial pro-
gress and review the quality and completeness of data.
The TSC will include an independent chairperson not
involved directly with the study, one clinical and one
methodological expert who are also not involved with
the study, and a principal investigator of the study. Our
trained diabetes nurses will be responsible for all aspects
of local organization, such as identifying and recruiting
participants, and RAs will be responsible for obtaining
informed consent. A formal data monitoring committee
(DMC) was not considered for the conduct of this study
as this will be a low-risk intervention; however, the trial
will be reviewed by national (every 6-month) and institu-
tional (every 2-month) Ethics Committee Review Board
members throughout the trial period. A Stakeholder and
Public Involvement Group (SPIG) was also not formed
as the study will be mainly led by the trained diabetes
nurses.
Discussion
To our knowledge, this study is the first to include a siz-
able number of diabetes and prediabetes participants in
a community-based setting and a continuum of care
program run by diabetes nurses. The priority health
problems of the target population, the potential solution
of the problem, recruitment strategies and intervention
delivery formats were discussed early on by the study-
specific collaborative partners in DH and the commu-
nity, which will lead to the success of the program.
The results of this study may provide much-needed
evidence for the policy-makers on the clinical effective-
ness, cost-effectiveness and implementation effectiveness
of nurse-led continuum of care for people with diabetes
and prediabetes in resource-limited settings. Many low-
income countries now face a double burden of chronic
diseases and infectious diseases. But large trials have
been rarely conducted in those settings in low-income
countries. This proposal has several unique features.
First, although nurse-led diabetes prevention and man-
agement programs have been tested earlier in different
settings, this is unique because it addresses the full con-
tinuum of care from the level of awareness and detection
to management and follow-up all led by nurses. Second,
the study focuses not only on clinical outcomes but also
on implementation outcomes. The nurse-led continuum
of care may theoretically improve health among people
with diabetes but also improve adoption of DCT-3-
recommended and evidence-based individual interven-
tion elements. We will also use some innovative strat-
egies to assess program implementation fidelity and
quality, such as the use of standardized patients. Third,
the study builds a culturally tailored and locally context-
ual training program for nurses utilizing the existing
training programs of the International Diabetes Feder-
ation and the American Diabetes Association. Fourth,
the study utilizes a unique setting of suburban tertiary-
level community-based health institutions that have an
extensive network of health centers in rural areas as
well. Hence, the experience we gain from this project
will be easily translated into larger health care systems.
Fifth, we have designed the trial, taking implementation,
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feasibility and sustainability into full consideration. For
instance, we did not offer free care to all program partic-
ipants in the trial as that will not be sustainable once the
program stops.
Although this trial may hold promise for better clinical
and implementation outcomes, it is not without poten-
tial limitations. We will have a large sample size, but the
setting of the study may not represent the entire nation,
thus limiting the generalizability of our findings. How-
ever, our setting will cover both public and private
health sectors and may serve as a proxy for the Nepalese
population.
Trial status
The protocol is the first version as we have not changed
any information after registering in the ClinicalTrials.gov
registry on 18 October 2019. We have not yet started
the recruitment of our sample. The approximate date
when recruitment will be completed will be the end of
December 2020.
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